SMAD3 and gastric cancer: Treatment with melatonin suppressed gastric cancer (Figure 3) via upregulation of miR-16-5p expression and downregulation of SMAD3 (Zhu et al., 2018), indicating that the TGF-β/SMAD pathway might be a possible molecular mechanism by which melatonin precludes cancer progression.